Perspectives
Patients with diabetes show poor adherence to heart disease drugs
Adherence to heart disease therapies dropped by half within one year
February 21, 2019Adherence to add-on therapies for heart disease dropped by half within one year for patients new to diabetes with heart disease, increasing risks for heart attacks or strokes
This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.
- Glucagon like peptide-1 agonists (GLP-1)
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
Dipeptidyl peptidase-4 inhibitors (DPP-4i)
All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90% in their clinical trials.)
Related news
Perspectives
March 27, 2024
Drug Approvals Monthly Update: March 2024
Critical updates in an ever-changing environment
Perspectives
March 27, 2024
Clinical News: March 2024
Your monthly source for drug information highlights
Perspectives
March 14, 2024
High-Cost Therapy Profile
Detailed information about Sotatercept Subcutaneous (SC)